Proxy Materials for RegeneRx Annual Meeting - September 10, 2014

Link to document.

Shareholder letter - Thursday May 22, 2014

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

September 3, 2014
RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement

July 15, 2014
New Report: Thymosin β4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice

July 7, 2014
RegeneRx’s Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259

June 23, 2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye

June 10, 2014
RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference

May 22, 2014
RegeneRx Issues Letter to Shareholders

April 21, 2014
RegeneRx Receives Notice of Allowance for U.S. Patent for Treatment of Stroke